Pds Biotechnology Corp Stock Today
| PDSB Stock | USD 1.67 0.02 1.21% |
Performance0 of 100
| Odds Of DistressOver 70
|
PDS Biotechnology is trading at 1.67 as of the 23rd of December 2024, a 1.21% increase since the beginning of the trading day. The stock's open price was 1.65. PDS Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 23rd of November 2024 and ending today, the 23rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of October 2015 | Category Healthcare | Classification Health Care |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. Pds Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 37.41 M outstanding shares of which 3.88 M shares are at this time shorted by private and institutional investors with about 10.47 trading days to cover. More on PDS Biotechnology Corp
Moving together with PDS Stock
Moving against PDS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PDS Stock Highlights
| President CEO, Director | Frank BeduAddo | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsPDS Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PDS Biotechnology's financial leverage. It provides some insight into what part of PDS Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
PDS Biotechnology Corp (PDSB) is traded on NASDAQ Exchange in USA. It is located in 303A College Road East, Princeton, NJ, United States, 08540 and employs 25 people. PDS Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.73 M. PDS Biotechnology Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.41 M outstanding shares of which 3.88 M shares are at this time shorted by private and institutional investors with about 10.47 trading days to cover.
PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PDS Biotechnology Probability Of Bankruptcy
Ownership AllocationPDS Biotechnology owns a total of 37.41 Million outstanding shares. PDS Biotechnology holds 3.99 pct. of its outstanding shares held by insiders and 12.35 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PDS Ownership Details
PDS Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Commonwealth Equity Services Inc | 2024-09-30 | 78.4 K | |
| Amussen, Hunsaker & Associates Incorporated | 2024-09-30 | 75 K | |
| Xtx Topco Ltd | 2024-09-30 | 67.2 K | |
| Sherbrooke Park Advisers Llc | 2024-09-30 | 40.2 K | |
| Vontobel Holding Ltd. | 2024-09-30 | 40 K | |
| Bank Of New York Mellon Corp | 2024-09-30 | 29.3 K | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 28.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 27.4 K | |
| Bank Of America Corp | 2024-09-30 | 27 K | |
| Vanguard Group Inc | 2024-09-30 | 1.5 M | |
| Blackrock Inc | 2024-06-30 | 487 K |
PDS Biotechnology Historical Income Statement
PDS Stock Against Markets
PDS Biotechnology Corporate Management
| Joe Dervan | VP Development | Profile | |
| Lars MBA | Chief Officer | Profile | |
| Deanne Randolph | Head Relations | Profile | |
| Gregory Conn | Chief Scientific Officer | Profile | |
| Spencer JD | Senior Counsel | Profile | |
| Nathalie Riebel | VP Operations | Profile | |
| Janetta Trochimiuk | Controller | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.